Clinical Trial - Trial jRCT2031220659
Access comprehensive clinical trial information for jRCT2031220659 through Pure Global AI's free database. This phase not specified trial is sponsored by Astrazeneca K.K and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD).
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Japan Registry Clinical Trial data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
jRCT2031220659
Recruiting
Trial Details
Japan Registry Clinical Trial • jRCT2031220659
Untitled Trial
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD. (PROSPERO)
Study Focus
Interventional
Sponsor & Location
Astrazeneca K.K
Argentina;Belgium;Bulgaria;Canada;Czech;Denmark;Finland;Hungary;India;Mexico;Netherlands;Norway;Port
Timeline & Enrollment
N/A
N/A
N/A
ICD-10 Classifications
Other chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease, unspecified
Other specified chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease with acute exacerbation, unspecified
Chronic obstructive pulmonary disease with acute lower respiratory infection
Data Source
Japan Registry Clinical Trial
jRCT2031220659
Non-Device Trial